 |
|
COMMENTS AND OPINIONS
Concerns About Bone Safety of Tricyclic Antidepressant Therapy—Reply
Susan Diem, MD, MPH;
Terri Blackwell, MA;
Katie L. Stone, PhD;
Kristine Yaffe, MD;
Elizabeth Haney, MD;
Michael Bliziotes, MD;
Kristine E. Ensrud, MD, MPH
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In reply
We agree that a definitive conclusion about TCAs and their possible effects on change in bone mineral density cannot be made based on our analysis. As we discussed in our article,1 TCAs are often prescribed for indications other than depression and, when prescribed for conditions such as insomnia or chronic pain, are often prescribed at low doses. Type II error is certainly possible, given our smaller number of TCA users. Based on our number of TCA users and nonusers and the standard deviation for their rates of bone loss, we had 80% power to detect a difference of 0.35 in the means of the annualized percentage change in total hip bone mineral density.
Our finding of no association between TCA use and increased . . . [Full Text of this Article]
AUTHOR INFORMATION
RELATED ARTICLE
Use of Antidepressants and Rates of Hip Bone Loss in Older Women: The Study of Osteoporotic Fractures
Susan J. Diem, Terri L. Blackwell, Katie L. Stone, Kristine Yaffe, Elizabeth M. Haney, Michael M. Bliziotes, and Kristine E. Ensrud
Arch Intern Med. 2007;167(12):1240-1245.
ABSTRACT
| FULL TEXT
RELATED LETTER
Concerns About Bone Safety of Tricyclic Antidepressant Therapy
Wee-Shiong Lim and Mark Chan
Arch Intern Med. 2008;168(4):435-436.
EXTRACT
| FULL TEXT
|
